BR112022018345A2 - Compostos para tratar ou inibir a recorrência de leucemia mieloide aguda - Google Patents
Compostos para tratar ou inibir a recorrência de leucemia mieloide agudaInfo
- Publication number
- BR112022018345A2 BR112022018345A2 BR112022018345A BR112022018345A BR112022018345A2 BR 112022018345 A2 BR112022018345 A2 BR 112022018345A2 BR 112022018345 A BR112022018345 A BR 112022018345A BR 112022018345 A BR112022018345 A BR 112022018345A BR 112022018345 A2 BR112022018345 A2 BR 112022018345A2
- Authority
- BR
- Brazil
- Prior art keywords
- myeloid leukemia
- acute myeloid
- compounds
- treatment
- inhibiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/079464 WO2021184154A1 (en) | 2020-03-16 | 2020-03-16 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| PCT/US2021/022322 WO2021188417A1 (en) | 2020-03-16 | 2021-03-15 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022018345A2 true BR112022018345A2 (pt) | 2022-11-08 |
Family
ID=77767943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018345A BR112022018345A2 (pt) | 2020-03-16 | 2021-03-15 | Compostos para tratar ou inibir a recorrência de leucemia mieloide aguda |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11963960B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4121430A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7744358B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102990081B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115298180B (cg-RX-API-DMAC7.html) |
| AR (1) | AR121570A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020436612A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022018345A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3168988A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296296A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011407A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20230461A1 (cg-RX-API-DMAC7.html) |
| PH (1) | PH12022552169A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI899184B (cg-RX-API-DMAC7.html) |
| WO (2) | WO2021184154A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| CA3182276A1 (en) | 2020-05-08 | 2021-12-02 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
| AU2021289345A1 (en) * | 2020-06-08 | 2023-01-19 | Halia Therapeutics, Inc. | Inhibitors of NEK7 kinase |
| CN114075190A (zh) | 2020-08-20 | 2022-02-22 | 北京诺诚健华医药科技有限公司 | 杂环类btk抑制剂 |
| CN113861179A (zh) * | 2021-10-22 | 2021-12-31 | 上海应用技术大学 | 一种新型flt3激酶抑制剂及其合成与应用 |
| WO2025124429A1 (zh) * | 2023-12-11 | 2025-06-19 | 北京康辰药业股份有限公司 | 芳香胺化合物及其药物组合物、应用 |
| WO2025151010A1 (ko) * | 2024-01-11 | 2025-07-17 | 주식회사 펠레메드 | 신규한 피롤로트리아진 유도체 및 이의 용도 |
| KR20250157634A (ko) | 2024-04-29 | 2025-11-05 | 대한민국(질병관리청 국립보건연구원장) | Bax 활성제를 유효성분으로 포함하는 항-hiv-1 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9808281A (pt) | 1997-03-19 | 2000-05-16 | Basf Ag | Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto |
| NZ510588A (en) | 1998-09-18 | 2003-08-29 | Abbott Gmbh & Co | Pyrrolopyrimidines as protein kinase inhibitors |
| US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| KR20020088406A (ko) * | 1999-09-17 | 2002-11-27 | 애보트 게엠베하 운트 콤파니 카게 | 치료제로서의 피라졸로피리미딘 |
| MXPA03008560A (es) * | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| WO2005074603A2 (en) * | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| BRPI0619146A2 (pt) | 2005-12-02 | 2011-09-13 | Bayer Pharmaceuticals Corp | derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis |
| US7772231B2 (en) | 2005-12-29 | 2010-08-10 | Abbott Laboratories | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors |
| EP2139487B1 (en) | 2007-03-28 | 2015-11-11 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| ES2396613T3 (es) | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopirazinas e imidazotriazinas sustituidas |
| JP6327713B2 (ja) | 2012-07-27 | 2018-05-23 | 国立研究開発法人理化学研究所 | 急性骨髄性白血病の治療又は再発抑制剤 |
| USRE48175E1 (en) * | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| US10266535B2 (en) | 2015-01-21 | 2019-04-23 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Inhibitor of FLT3 kinase and use thereof |
| GB201508747D0 (en) | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
| US20190255056A1 (en) | 2016-09-15 | 2019-08-22 | Riken | A hck inhibitor and a bcl-2 inhibitor for treating acute myeloid leukemia |
| CN118027041A (zh) * | 2019-05-31 | 2024-05-14 | 西藏海思科制药有限公司 | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 |
| AU2020301399B2 (en) | 2019-06-24 | 2025-12-18 | Dana-Farber Cancer Institute, Inc. | HCK degraders and uses thereof |
| CN114746095B (zh) | 2019-10-08 | 2025-01-24 | 达纳-法伯癌症研究所有限公司 | Hck作为myd88突变疾病的治疗靶点 |
| MX2022008148A (es) * | 2020-01-02 | 2022-07-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Inhibidores de btk. |
| AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
-
2020
- 2020-03-16 AU AU2020436612A patent/AU2020436612A1/en active Pending
- 2020-03-16 WO PCT/CN2020/079464 patent/WO2021184154A1/en not_active Ceased
-
2021
- 2021-03-12 AR ARP210100645A patent/AR121570A1/es not_active Application Discontinuation
- 2021-03-15 MX MX2022011407A patent/MX2022011407A/es unknown
- 2021-03-15 CA CA3168988A patent/CA3168988A1/en active Pending
- 2021-03-15 US US17/201,827 patent/US11963960B2/en active Active
- 2021-03-15 JP JP2022555625A patent/JP7744358B2/ja active Active
- 2021-03-15 IL IL296296A patent/IL296296A/en unknown
- 2021-03-15 EP EP21772015.0A patent/EP4121430A4/en active Pending
- 2021-03-15 AU AU2021239828A patent/AU2021239828B2/en active Active
- 2021-03-15 PH PH1/2022/552169A patent/PH12022552169A1/en unknown
- 2021-03-15 KR KR1020227035324A patent/KR102990081B1/ko active Active
- 2021-03-15 CN CN202180016180.0A patent/CN115298180B/zh active Active
- 2021-03-15 BR BR112022018345A patent/BR112022018345A2/pt not_active IP Right Cessation
- 2021-03-15 PE PE2022001990A patent/PE20230461A1/es unknown
- 2021-03-15 WO PCT/US2021/022322 patent/WO2021188417A1/en not_active Ceased
- 2021-03-16 TW TW110109254A patent/TWI899184B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| CN115298180A (zh) | 2022-11-04 |
| PH12022552169A1 (en) | 2024-01-29 |
| JP2023518035A (ja) | 2023-04-27 |
| EP4121430A1 (en) | 2023-01-25 |
| CA3168988A1 (en) | 2021-09-23 |
| WO2021184154A1 (en) | 2021-09-23 |
| AU2021239828A1 (en) | 2025-04-03 |
| KR102990081B1 (ko) | 2026-07-10 |
| AR121570A1 (es) | 2022-06-15 |
| WO2021188417A1 (en) | 2021-09-23 |
| US20210299128A1 (en) | 2021-09-30 |
| TW202200583A (zh) | 2022-01-01 |
| JP7744358B2 (ja) | 2025-09-25 |
| AU2020436612A1 (en) | 2022-09-01 |
| AU2021239828B2 (en) | 2025-06-26 |
| TWI899184B (zh) | 2025-10-01 |
| US11963960B2 (en) | 2024-04-23 |
| PE20230461A1 (es) | 2023-03-14 |
| IL296296A (en) | 2022-11-01 |
| CN115298180B (zh) | 2025-06-10 |
| KR20220154164A (ko) | 2022-11-21 |
| MX2022011407A (es) | 2022-10-13 |
| EP4121430A4 (en) | 2024-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552169A1 (en) | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | |
| MX2023013912A (es) | Metodos para inhibir ras. | |
| MX2018010678A (es) | Inhibidores de mcl-1 indolicos sustituidos. | |
| ZA202003176B (en) | Compounds useful as kinase inhibitors | |
| EA202191730A1 (ru) | Ингибиторы kif18a | |
| CU20210029A7 (es) | Inhibidores de proteína tirosina fosfatasa shp2 útiles en el tratamiento de enfermedades | |
| PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
| ECSP22053394A (es) | Inhibidores de sarm1 | |
| ECSP23012981A (es) | Inhibidores de sarm1 | |
| PE20181803A1 (es) | Inhibidores de mcl-1 macrociclicos para tratar el cancer | |
| PY2263012A (es) | Composiciones para el control fúngico y métodos relacionados | |
| EA201992322A2 (ru) | Соединения и композиции для лечения гематологических расстройств | |
| GEAP202316332A (en) | Cdk2 inhibitors and methods of using the same | |
| JOP20230033A1 (ar) | عملية ومركبات وسيطة لتحضير مثبط Jak | |
| CO2022009852A2 (es) | Inhibidores de la proteína leucemia once-diecinueve (enl)/af9 yeats | |
| DOP2025000213A (es) | [1,3]tiazolo[4,5-d]-pirimidin-7-onas como inhibidores de la nox4 | |
| MX2020012291A (es) | Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario. | |
| GEAP202416612A (en) | Tricyclic urea compounds as jak2 v617f inhibitors | |
| MX2020012253A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiazepinona para el tratamiento del carcinoma quistico adenoide. | |
| BR112022005895A2 (pt) | Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2 | |
| BRPI0407793A (pt) | tratamento de osteólise excessiva com compostos de indolinona | |
| BR112023020554A2 (pt) | Combinações de inibidores de lsd1 para o tratamento de cânceres mieloides | |
| EP3998284A4 (en) | Composition for preventing, ameliorating or treating immune checkpoint inhibitor-resistant cancer | |
| BR112018075086A2 (pt) | derivados de pirazolilaminobenzimidazol como inibidores de jak | |
| AR119557A1 (es) | Compuestos de 7,8-dihidro-4h-pirazolo[4,3-c]azepina-6-ona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11N | Dismissal: publication cancelled [chapter 11.14 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 11.1 NA RPI NO 2777 DE 26/03/2024 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2871 DE 13-01-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |